Cambrex Corporation (NYSE:CBM) – First Analysis reduced their Q2 2018 earnings per share (EPS) estimates for Cambrex Corporation in a note issued to investors on Monday. First Analysis analyst S. Schwartz now forecasts that the biotechnology company will post earnings per share of $0.74 for the quarter, down from their prior forecast of $0.87.

Several other research firms have also commented on CBM. BidaskClub upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a research report on Friday, August 4th. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Craig Hallum restated a “buy” rating and set a $60.00 price objective (down previously from $70.00) on shares of Cambrex Corporation in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. Cambrex Corporation currently has an average rating of “Hold” and an average price target of $62.33.

TRADEMARK VIOLATION WARNING: “First Analysis Comments on Cambrex Corporation’s Q2 2018 Earnings (CBM)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/14/first-analysis-comments-on-cambrex-corporations-q2-2018-earnings-cbm.html.

Shares of Cambrex Corporation (NYSE CBM) traded down $0.45 during trading hours on Tuesday, hitting $45.90. 598,200 shares of the company’s stock were exchanged, compared to its average volume of 331,166. The firm has a market capitalization of $1,519.24, a PE ratio of 14.62 and a beta of 2.26. Cambrex Corporation has a 52 week low of $42.55 and a 52 week high of $62.95.

Cambrex Corporation (NYSE:CBM) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.08. The firm had revenue of $112.60 million for the quarter, compared to analysts’ expectations of $108.44 million. Cambrex Corporation had a net margin of 18.79% and a return on equity of 23.42%. The firm’s quarterly revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.47 earnings per share.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning raised its position in Cambrex Corporation by 162.6% during the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 1,093 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Cambrex Corporation by 9.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 150 shares during the last quarter. YorkBridge Wealth Partners LLC grew its holdings in Cambrex Corporation by 5.2% during the second quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 97 shares during the last quarter. Riverhead Capital Management LLC grew its holdings in Cambrex Corporation by 90.3% during the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,264 shares during the last quarter. Finally, Advisor Group Inc. grew its holdings in Cambrex Corporation by 29.8% during the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 615 shares during the last quarter.

In other news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the completion of the sale, the chief executive officer now directly owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $51.53, for a total transaction of $618,360.00. Following the completion of the sale, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at $4,912,251.84. The disclosure for this sale can be found here. 2.48% of the stock is currently owned by corporate insiders.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Earnings History and Estimates for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.